Transporting silence: Design of carriers for siRNA to angiogenic endothelium

AJ Mixson; AM Ansari; MHAM Fens; QQ Tang; Q Zhou; G Molema; PY Lu; PV Scaria; G Storm; MC Woodle

doi:10.1016/j.jconrel.2005.05.018

Transporting silence: Design of carriers for siRNA to angiogenic endothelium

AJ Mixson, AM Ansari, MHAM Fens, QQ Tang, Q Zhou, G Molema, PY Lu, PV Scaria, G Storm, MC Woodle

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

Abstract

The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression. To achieve therapeutic success, however, several hurdles must be overcome including rapid clearance, nuclease degradation, and inefficient intracellular localization. In this presentation, we discuss design strategies for development of self-assembling nanoscale carriers for neovasculature targeted delivery of siRNA inhibiting tumor or ocular angiogenesis. (c) 2005 Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	5-14
Number of pages	10
Journal	Journal of Controlled Release
Volume	109
Issue number	1-3
DOIs	https://doi.org/10.1016/j.jconrel.2005.05.018
Publication status	Published - 5-Dec-2005
Event	12th International Symposium on Recent Advances in Drug Delivery Systems - Duration: 21-Feb-2005 → 24-Feb-2005

Keywords

RNA interference
siRNA
drug targeting
angiogenesis
GROWTH-FACTOR
THERAPY
PEPTIDE
CANCER
CELLS
DELIVERY
IDENTIFICATION
THERAPEUTICS
INFLAMMATION
INHIBITION

Access to Document

10.1016/j.jconrel.2005.05.018

Cite this

@article{bc8322856a43413098c0de8a4f460118,

title = "Transporting silence: Design of carriers for siRNA to angiogenic endothelium",

abstract = "The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression. To achieve therapeutic success, however, several hurdles must be overcome including rapid clearance, nuclease degradation, and inefficient intracellular localization. In this presentation, we discuss design strategies for development of self-assembling nanoscale carriers for neovasculature targeted delivery of siRNA inhibiting tumor or ocular angiogenesis. (c) 2005 Elsevier B.V. All rights reserved.",

keywords = "RNA interference, siRNA, drug targeting, angiogenesis, GROWTH-FACTOR, THERAPY, PEPTIDE, CANCER, CELLS, DELIVERY, IDENTIFICATION, THERAPEUTICS, INFLAMMATION, INHIBITION",

author = "AJ Mixson and AM Ansari and MHAM Fens and QQ Tang and Q Zhou and G Molema and PY Lu and PV Scaria and G Storm and MC Woodle",

year = "2005",

month = dec,

day = "5",

doi = "10.1016/j.jconrel.2005.05.018",

language = "English",

volume = "109",

pages = "5--14",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier Bedrijfsinformatie b.v.",

number = "1-3",

note = "12th International Symposium on Recent Advances in Drug Delivery Systems ; Conference date: 21-02-2005 Through 24-02-2005",

}

TY - JOUR

T1 - Transporting silence

T2 - 12th International Symposium on Recent Advances in Drug Delivery Systems

AU - Mixson, AJ

AU - Ansari, AM

AU - Fens, MHAM

AU - Tang, QQ

AU - Zhou, Q

AU - Molema, G

AU - Lu, PY

AU - Scaria, PV

AU - Storm, G

AU - Woodle, MC

PY - 2005/12/5

Y1 - 2005/12/5

N2 - The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression. To achieve therapeutic success, however, several hurdles must be overcome including rapid clearance, nuclease degradation, and inefficient intracellular localization. In this presentation, we discuss design strategies for development of self-assembling nanoscale carriers for neovasculature targeted delivery of siRNA inhibiting tumor or ocular angiogenesis. (c) 2005 Elsevier B.V. All rights reserved.

AB - The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression. To achieve therapeutic success, however, several hurdles must be overcome including rapid clearance, nuclease degradation, and inefficient intracellular localization. In this presentation, we discuss design strategies for development of self-assembling nanoscale carriers for neovasculature targeted delivery of siRNA inhibiting tumor or ocular angiogenesis. (c) 2005 Elsevier B.V. All rights reserved.

KW - RNA interference

KW - siRNA

KW - drug targeting

KW - angiogenesis

KW - GROWTH-FACTOR

KW - THERAPY

KW - PEPTIDE

KW - CANCER

KW - CELLS

KW - DELIVERY

KW - IDENTIFICATION

KW - THERAPEUTICS

KW - INFLAMMATION

KW - INHIBITION

U2 - 10.1016/j.jconrel.2005.05.018

DO - 10.1016/j.jconrel.2005.05.018

M3 - Article

VL - 109

SP - 5

EP - 14

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1-3

Y2 - 21 February 2005 through 24 February 2005

ER -